{
    "2018-04-11": [
        [
            {
                "time": "2018-04-11",
                "original_text": "Novartis’s Valuation and Analysts’ Recommendations on April 11",
                "features": {
                    "keywords": [
                        "Novartis",
                        "valuation",
                        "analysts",
                        "recommendations"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Incyte Expected to Report Robust Revenue Growth in Fiscal 2018",
                "features": {
                    "keywords": [
                        "Incyte",
                        "revenue",
                        "growth",
                        "fiscal 2018"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-09",
                "original_text": "Novartis’s Stock Performance following the AveXis Agreement",
                "features": {
                    "keywords": [
                        "Novartis",
                        "stock",
                        "performance",
                        "AveXis",
                        "agreement"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous",
                "features": {
                    "keywords": [
                        "little-known",
                        "company",
                        "Gilead",
                        "Celgene",
                        "investors",
                        "nervous"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-09",
                "original_text": "Novartis Enters Agreement to Acquire AveXis",
                "features": {
                    "keywords": [
                        "Novartis",
                        "agreement",
                        "acquire",
                        "AveXis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis",
                "features": {
                    "keywords": [
                        "biotech",
                        "stock",
                        "Spectrum",
                        "Incyte",
                        "AveXis",
                        "Novartis"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "mixed",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            },
            {
                "time": "2018-04-12",
                "original_text": "Alexion's Deal Discipline Sure Beats a Previous Disaster",
                "features": {
                    "keywords": [
                        "Alexion",
                        "deal",
                        "discipline",
                        "disaster"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous",
                "features": {
                    "keywords": [
                        "little-known",
                        "company",
                        "Gilead",
                        "Celgene",
                        "investors",
                        "nervous"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-05",
                "original_text": "Why CASI Pharmaceuticals Stock Rose Last Week",
                "features": {
                    "keywords": [
                        "CASI",
                        "Pharmaceuticals",
                        "stock",
                        "rose",
                        "last week"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-14",
                "original_text": "The Swiss Stock Market Dropped On Syria Concerns",
                "features": {
                    "keywords": [
                        "Swiss",
                        "stock",
                        "market",
                        "dropped",
                        "Syria",
                        "concerns"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}